Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Robert F. Kennedy Jr. petitioned the F.D.A. to revoke authorization of the shots at a time when they were in high demand and ...

Japan from mid-October plans to administer a new type of vaccine in booster shots designed to protect ... Pfizer Inc. and Moderna Inc. have been developing their versions of the bivalent vaccine.

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future ...

The third scenario, in which the booster dose was with the Pfizer vaccine, showed the highest percentages of effectiveness: 56.8% against symptomatic infections and 85.5% against severe cases.

The financial package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines ... and at a time when Moderna is preparing to advance its ...

Only by tapping into this earlier work was Moderna able to bring its mRNA vaccines to market so swiftly, the suits claim. It is not the first time that GSK has flexed its legal muscles in defence ...

The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...

to two new-generation COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna, both targeting the new Omicron subvariants BA.4 and BA.5. The US regulator has cleared a 30 µg booster dose of a new ...

Booster Now ... can be prevented with only two shots of improved vaccine, with a third shot later to give “prolonged immunity.” Contact us at [email protected] ...